By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885


SEARCH JOBS


Industry
Biotechnology






Company News
Janssen-Cilag International NV (JNJ)’s IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion For Expanded Use In Previously Untreated Chronic Lymphocytic Leukaemia Patients 4/29/2016 10:12:50 AM
CHMP Issues A Positive Opinion On Janssen-Cilag International NV (JNJ)’s Single-Agent DARZALEX (Daratumumab) 4/1/2016 10:12:16 AM
Janssen-Cilag International NV (JNJ) Receives CHMP Positive Opinion For TREVICTA (Paliperidone Palmitate A 3-Monthly Injection) Recommending Approval In The European Union For The Maintenance Treatment Of Schizophrenia 4/1/2016 10:10:36 AM
Janssen-Cilag International NV (JNJ) Release: Greater Survival Benefit Shown In Men With Early And Less Aggressive Metastatic Castration-Resistant Prostate Cancer Treated With ZYTIGA Plus Prednisone 3/14/2016 11:22:14 AM
Janssen-Cilag International NV (JNJ) Presents New Data Assessing OLYSIO (Simeprevir) In Combination With Sofosbuvir In Genotype 4 Infected HCV Patients In Egypt 11/16/2015 11:48:30 AM
Janssen-Cilag International NV (JNJ) Submits Application To The European Medicines Agency To Expand Use Of IMBRUVICA® (Ibrutinib) In Previously Untreated Chronic Lymphocytic Leukaemia Patients 11/3/2015 11:01:56 AM
Janssen-Cilag International NV (JNJ) Receives Positive CHMP Opinion Recommending EDURANT (rilpivirine) For The Treatment Of Adolescents Aged 12 To <18 Years With HIV-1 Infection 10/26/2015 9:19:07 AM
Janssen-Cilag International NV (JNJ) Release: First Data From Europe’s First And Largest Prospective Observational Study Of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presented At The 2015 European Cancer Congress (ECC2015) 9/29/2015 12:22:16 PM
Janssen-Cilag International NV (JNJ)’s Daratumumab Accepted For Accelerated CHMP Assessment For Treatment Of European Patients With Heavily Pre-Treated Multiple Myeloma 9/25/2015 10:47:01 AM
Janssen-Cilag International NV (JNJ) Submits European Extension Marketing Authorisation Application For Paliperidone Palmitate Once-Every-Three-Months Formulation 8/21/2015 9:29:19 AM
12345
//-->